Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 29, 2006.
Business Overview: Greatbatch designs and manufactures critical components for implantable medical devices (IMC segment) and high-performance batteries for commercial applications (ECP segment), including oil and gas, aerospace, and oceanographic markets.
Key Financial Metrics
| Metric | Q3 2006 | Q3 2005 | 9M 2006 | 9M 2005 |
|---|---|---|---|---|
| Sales | $69.3 million | $62.4 million | $208.0 million | $182.2 million |
| Operating Income | $4.1 million | $1.4 million | $21.2 million | $15.7 million |
| Net Income | $3.2 million | $0.8 million | $14.7 million | $10.0 million |
| Diluted EPS | $0.15 | $0.03 | $0.65 | $0.46 |
| Operating Margin | 5.9% | 2.3% | 10.2% | 8.6% |
| Cash & Equivalents | $55.8 million | $46.4 million (Dec 2005) | N/A | |
| Short-term Investments | $72.4 million | $65.7 million (Dec 2005) | N/A | |
| Working Capital | $190.1 million | $152.0 million (Dec 2005) | N/A | |
| Long-term Debt | $170.0 million | $170.0 million (Dec 2005) | N/A | |
| Operating Cash Flow (9M) | N/A | $24.8 million | $32.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 11% in Q3 and 14% for the nine months ended September 29, 2006, compared to the prior year. The IMC segment grew 5% (Q3) and 11% (9M), while the ECP segment surged 49% (Q3) and 32% (9M) driven by oil and gas demand.
- Profitability: Operating income rose 184% in Q3 and 35% for the nine-month period. Net income increased 328% in Q3 and 47% for the nine months.
- Expense Drivers:
- Stock-Based Compensation: Adoption of SFAS No. 123(R) in 2006 added $1.1 million (Q3) and $2.9 million (9M) in incremental expense compared to prior year pro forma.
- Restructuring: "Other operating expense" decreased 20% in Q3 and 12% for the nine months due to lower facility consolidation costs compared to 2005, partially offset by a $4.4 million write-off of a battery test system in Q3 2006.
- R&D: Research and development costs increased 18% (Q3) and 37% (9M) due to planned headcount increases for new product development.
- Tax Rate: The effective tax rate decreased to 24.3% in Q3 2006 from 30.0% in Q3 2005, attributed to tax savings initiatives and the Extraterritorial Income Exclusion.
Guidance, Outlook, and Risks
- Guidance Revision: Following a November 3, 2006, decision to consolidate corporate and business unit structures (eliminating ~40 positions), the Company reduced its full-year 2006 diluted EPS guidance by $0.06 to a range of $0.65 - $0.71 (previously $0.71 - $0.77). Severance costs are estimated at $2.1 - $2.3 million, primarily in Q4.
- Strategic Outlook: Management expects annual gross savings of $8.0 - $10.0 million from the consolidation plan, with $6.0 million reinvested in R&D. The Company anticipates continued growth in the IMC segment driven by new Q-Series batteries and the ECP segment driven by oil and gas markets.
- Facility Consolidation: The Carson City facility closure is delayed until Q1 2007 pending regulatory approval. The Columbia facility move is on track for mid-2007 completion.
- Risks:
- Customer Concentration: Three customers (Boston Scientific, St. Jude Medical, Medtronic) accounted for approximately 66% of total sales in the first nine months of 2006.
- Field Actions: Prior year sales included $3-$5 million (Q3) and $6-$8 million (9M) related to customer field actions (recalls/replacements), creating a high base for comparison.
- Accounting Standards: The Company is evaluating the impact of SFAS No. 157 (Fair Value) and FIN No. 48 (Income Tax Uncertainty), effective in future periods.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with the top three customers representing 66% of revenue.
- Restructuring Costs: Monitor Q4 2006 results for the anticipated $2.1 - $2.3 million severance charge and the impact on the revised EPS guidance.
- Facility Delays: Track the regulatory approval status for the Carson City facility closure to assess potential cost overruns.
- Stock-Based Compensation: Review future quarters for the continued impact of SFAS No. 123(R) on operating margins.
- Asset Write-offs: Assess the $4.4 million Q3 write-off of the battery test system to ensure no further development costs are at risk.